| Primary |
| Radiotherapy |
47.2% |
| Neoplasm Malignant |
13.9% |
| Prophylaxis |
11.6% |
| Adverse Drug Reaction |
7.3% |
| Tongue Neoplasm Malignant Stage Unspecified |
3.3% |
| Chemotherapy |
2.3% |
| Infection |
2.0% |
| Malignant Respiratory Tract Neoplasm |
1.7% |
| Tonsil Cancer |
1.7% |
| Dry Mouth |
1.3% |
| Adenocarcinoma |
1.0% |
| Breast Cancer |
1.0% |
| Laryngeal Cancer |
1.0% |
| Ovarian Cancer |
1.0% |
| Burkitt's Lymphoma Stage Ii |
0.7% |
| Chemotherapy Cytokine Prophylaxis |
0.7% |
| Drug Use For Unknown Indication |
0.7% |
| Hypopharyngeal Cancer |
0.7% |
| Lung Neoplasm Malignant |
0.7% |
| Rectal Cancer |
0.7% |
|
| Vomiting |
23.4% |
| Weight Decreased |
9.8% |
| White Blood Cell Count Decreased |
8.8% |
| Rash Generalised |
7.3% |
| Stevens-johnson Syndrome |
7.3% |
| Pyrexia |
6.3% |
| Rash |
5.4% |
| Tachycardia |
3.9% |
| Hypotension |
2.9% |
| Skin Exfoliation |
2.9% |
| Stomatitis |
2.9% |
| Urinary Tract Infection |
2.9% |
| Loss Of Consciousness |
2.4% |
| Toxic Epidermal Necrolysis |
2.4% |
| Pneumonia |
2.0% |
| Rash Maculo-papular |
2.0% |
| Skin Lesion |
2.0% |
| Staphylococcal Infection |
2.0% |
| Tremor |
2.0% |
| Nausea |
1.5% |
|
| Secondary |
| Infection |
19.8% |
| Product Used For Unknown Indication |
19.0% |
| Unevaluable Event |
14.3% |
| Nausea |
7.9% |
| Neoplasm Malignant |
7.1% |
| Ovarian Cancer |
4.8% |
| Radiotherapy |
4.8% |
| Bone Marrow Conditioning Regimen |
4.0% |
| Prophylaxis |
3.2% |
| Head And Neck Cancer |
2.4% |
| Rectal Cancer |
2.4% |
| Constipation |
1.6% |
| Dyspepsia |
1.6% |
| Infection Parasitic |
1.6% |
| Vomiting |
1.6% |
| Anorexia |
0.8% |
| Ascites |
0.8% |
| Blood Calcium |
0.8% |
| Blood Urea Increased |
0.8% |
| Carcinoma In Situ |
0.8% |
|
| Urinary Tract Infection |
19.1% |
| Toxic Epidermal Necrolysis |
14.9% |
| White Blood Cell Count Decreased |
14.9% |
| Sepsis Syndrome |
12.8% |
| Syncope Vasovagal |
10.6% |
| Vomiting |
6.4% |
| Diastolic Dysfunction |
2.1% |
| Iris Adhesions |
2.1% |
| Myopericarditis |
2.1% |
| Nausea |
2.1% |
| Rash Pustular |
2.1% |
| Renal Tubular Necrosis |
2.1% |
| Skin Disorder |
2.1% |
| Tachycardia |
2.1% |
| Therapeutic Response Unexpected |
2.1% |
| Ventricular Hypertrophy |
2.1% |
|
| Concomitant |
| Metastases To Bone |
44.1% |
| Neoplasm Malignant |
17.6% |
| Premedication |
11.8% |
| Breast Cancer Female |
5.9% |
| Head And Neck Cancer |
5.9% |
| Non-small Cell Lung Cancer |
5.9% |
| Cancer Pain |
2.9% |
| Multiple Myeloma |
2.9% |
| Pain |
2.9% |
|
| Vertebroplasty |
20.8% |
| Headache |
8.3% |
| Skin Exfoliation |
8.3% |
| Dry Eye |
4.2% |
| Graft Versus Host Disease |
4.2% |
| Hot Flush |
4.2% |
| Hypoalbuminaemia |
4.2% |
| Lung Neoplasm |
4.2% |
| Mastoid Disorder |
4.2% |
| Mood Altered |
4.2% |
| Musculoskeletal Pain |
4.2% |
| Neoplasm Recurrence |
4.2% |
| Night Sweats |
4.2% |
| Rash |
4.2% |
| Staphylococcal Infection |
4.2% |
| Tooth Loss |
4.2% |
| Unresponsive To Verbal Stimuli |
4.2% |
| Vision Blurred |
4.2% |
|
| Interacting |
| Squamous Cell Carcinoma |
75.0% |
| Prophylaxis |
25.0% |
|
|
